A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.
A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days
Sponsor: GlaxoSmithKline
Terminated
This trial was terminated. No reason was provided.
A PHASE4 clinical study on Analgesia and Sedation, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE4
-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — May 2018 [monthly]
Terminated PHASE4
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .